Earnings reports for China biomedical companies continued to be released at a slower pace over the past five days. Lotus Pharma announced its revenues climbed an admirable 51% but net income dropped 27%; Sinobiomed emphasized its pipeline rather than its revenues, which are falling; and China Shenghuo Pharma said it will have to restate its reports because of irregularities; Smith & Nephew will expand two China manufacturing facilities; CRO Venturepharm Labs purchased 44% of the US CRO, Commonwealth Biotechnologies; and MicuRx Pharma picked its first preclinical development candidate, a next-generation antibiotic. More details...